1-20 of 38
Dajun Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Embryonic Ectoderm Development (EED) Inhibitor APG5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin Insufficiency in Preclinical Models of Anemia

Yifan Zhai, Yan Yin, Eric Liang, Hengbang Wang, Ping Min, Dajun Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5268.
https://doi.org/10.1182/blood-2023-185127
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Enhances Antitumor Effects of Chemotherapy in Philadelphia Chromosome-Positive (Ph⁺) Acute Lymphoblastic Leukemia (ALL)

Eric Liang, Ping Min, Yan Xiong, Bingxing Wu, Huidan Yu, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 5882.
https://doi.org/10.1182/blood-2023-189315
Published: 2023
Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Keshu Zhou, Mingyuan Sun, Xu Wei, Shuhua Yi, Junyuan Qi, Weiqi Nian, Guohui Cui, Jishi Wang, Xiaoping Zhang, Hong Cen, Fuling Zhou, Jianying Huang, Huilan Liu, Aizong Shen, Liangquan Geng, Ru Feng, Chongyuan Xu, Wenbin Qian, Fei Li, Lihong Liu, Caixia Li, Xielan Zhao, Jie Jin, Hongmei Jing, Dongmei Ji, Fangfang Lyu, Zi Chen, Lichuang Men, Hengbang Wang, Ke Zhang, Liang Xu, Zhang Zhang, Dajun Yang, Jianxiang Wang, Jianyong Li, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1900.
https://doi.org/10.1182/blood-2023-183071
Published: 2023
Journal Articles

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Sikander Ailawadhi, Asher A. Chanan-Khan, Costas K. Yannakou, Simon Gibbs, Jack Khouri, Zi Chen, Huanshan Guo, Mingyu Li, Mohammad Ahmad, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 2016.
https://doi.org/10.1182/blood-2023-188122
Published: 2023
Journal Articles

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Junyuan Qi, Xudong Wei, Qiubai Li, Chukang Chang, Fuling Zhou, Jianying Huang, Yu Zhang, Chongyuan Xu, Xiaowen Tang, Qian Jiang, Junmin Li, Qun Qin, Qun He, Sujun Gao, Liping Liu, Zi Chen, Min Yu, Jing Wang, Lichuang Men, Hengbang Wang, Mohammad Ahmad, Dajun Yang, Yifan Zhai, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5954.
https://doi.org/10.1182/blood-2023-184959
Published: 2023
Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Huafeng Wang, Xudong Wei, Qian Jiang, Wenjun He, Qiubai Li, Yang Liang, Jianyu Weng, Suning Chen, Hongbing Ma, Chukang Chang, Yajing Xu, Qun He, Zi Chen, Lihui Liu, Lichuang Men, Danhua Cong, Zhang Zhang, Dajun Yang, Yifan Zhai, Jie Jin, IV
Journal: Blood
Blood (2023) 142 (Supplement 1): 2925.
https://doi.org/10.1182/blood-2023-188489
Published: 2023
Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Elias Jabbour, Hagop M. Kantarjian, Paul B. Koller, Omer Jamy, Vivian G. Oehler, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Jorge Cortes, Huanshan Guo, Zi Chen, Lei Fu, Hengbang Wang, Lixin Jiang, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1798.
https://doi.org/10.1182/blood-2023-187744
Published: 2023
Journal Articles

MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)

Guangfeng Wang, Eric Liang, Ping Min, Yangfeng Ge, Bingxing Wu, Huidan Yu, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 9953–9954.
https://doi.org/10.1182/blood-2022-162666
Published: 2022
Journal Articles

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Tapan M. Kadia, Christopher Benton, Harry P. Erba, Mitul Gandhi, Moshe Y. Levy, Mary-Elizabeth M. Percival, Matthew Ulrickson, Habte Yimer, Min Yu, Zi Chen, Jing Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 11659–11660.
https://doi.org/10.1182/blood-2022-162627
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Elias Jabbour, Paul B. Koller, Vivian G. Oehler, Omer H Jamy, Sudipto Mukherjee, Anthony M. Hunter, Maria R. Baer, Joseph T. Beck, Zi Chen, Huanshan Guo, Lei Fu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian, Lixin Jiang, Cunlin Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 200–202.
https://doi.org/10.1182/blood-2022-162387
Published: 2022
Journal Articles

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Qian Jiang, Zongru Li, Ya-Zhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 198–199.
https://doi.org/10.1182/blood-2022-170868
Published: 2022
Journal Articles

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Matthew S. Davids, Asher Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kriachok, Hanna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Zvenyslava Maslyak, Andrew Proidakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison Winter, Tamila Lysa, Bulat Bakirov, Lei Fu, Zi Chen, Min Yu, Mingyu Li, Laura Glass, Mohammad Ahmad, Olena Karpenko, Iurii Osipov, Asit De, Ben Paudyal, Hengbang Wang, Robert Winkler, Nashat Gabrail, Vinod Ganju, Tatiana S. Konstantinova, Olga S. Samoylova, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 2326–2328.
https://doi.org/10.1182/blood-2022-160386
Published: 2022
Journal Articles

Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)

Chengcheng Fu, Zi Chen, Wensi Li, Lichuang Men, Depei Wu, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2021) 138 (Supplement 1): 4764.
https://doi.org/10.1182/blood-2021-151631
Published: 2021
Journal Articles

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Bing Z Carter, Wenjing Tao, Lauren B Ostermann, Hong Mu-Mosley, Po Yee Mak, Steffen Boettcher, Yuki Nishida, Ran Tao, Eric Lang, Yifan Zhai, Dajun Yang, Michael Andreeff
Journal: Blood
Blood (2021) 138 (Supplement 1): 3332.
https://doi.org/10.1182/blood-2021-148127
Published: 2021
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Jiang Qian, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yongping Song, Gongli Zhang, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yujun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3598.
https://doi.org/10.1182/blood-2021-153937
Published: 2021
Journal Articles

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

Mingyuan Sun, Junyuan Qi, Zi Chen, Hongli Zhang, Yongping Song, Aizong Shen, Huilan Liu, Jianying Huang, Fuling Zhou, Jie Jin, Ming Lu, Mohammad Ahmad, Lichuang Men, Wan Cen, Dajun Yang, Jianxiang Wang, Yifan Zhai
Journal: Blood
Blood (2021) 138 (Supplement 1): 3730.
https://doi.org/10.1182/blood-2021-152235
Published: 2021
Journal Articles

Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Matthew S. Davids, Tanya Siddiqi, Asher Chanan-Khan, Alan Skarbnik, Allison M. Winter, John M. Pagel, Carrie Smith, Nashat Gabrail, Tetiana Perekhrestenko, Halyna Pylypenko, Olena Kyselova, Olena Karpenko, Tetiana Popovska, Iryna Kriachok, Hanna Usenko, Andrew Proidakov, Vladimir Ivanov, Tamila Lysa, Elena Borisenkova, Bulat Bakirov, Les Lukavetsky, Olga Uspenskaya, Tatiana S. Konstantinova, Olga S. Samoylova, Zi Chen, Bo Huang, Mingyu Li, Mohammad Ahmad, Boyd Mudenda, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2021) 138 (Supplement 1): 1554.
https://doi.org/10.1182/blood-2021-152811
Published: 2021
Journal Articles

Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)

Guangfeng Wang, Eric Liang, Ping Ming, Li Rui, Chunyang Tang, Jing LV, Yangfeng Ge, Fei Zhang, Lvcheng Wang, Jingjin Shang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2021) 138 (Supplement 1): 2062.
https://doi.org/10.1182/blood-2021-152207
Published: 2021